CLINICAL TRIALS

You have access
Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region
Mathieu Choufani, Wissam Ghusn, Maureen Dubreuil and Joerg Ermann

The Journal of Rheumatology December 1 2025, 52 (12) 1245-1253; DOI: https://doi.org/10.3899/jrheum.2024-1013
You have access
A Systematic Review of Clinical Trial Designs and Outcome Measures in Sjögren Disease Randomized Controlled Trials
Maxime Beydon, Yann Nguyen, Rachael Gordon, Nathan Foulquier, Coralie Bouillot, Katherine M. Hammitt, Simon J. Bowman, Xavier Mariette, Divi Cornec, Sara S. McCoy and Raphaèle Seror

The Journal of Rheumatology September 1 2025, 52 (9) 858-872; DOI: https://doi.org/10.3899/jrheum.2024-1012
You have access
Role of CD19 Chimeric Antigen Receptor T Cell Therapy in Idiopathic Inflammatory Myopathies
Anushka Aggarwal, Maha Almackenzie and Rohit Aggarwal

The Journal of Rheumatology June 1 2025, 52 (6) 532-542; DOI: https://doi.org/10.3899/jrheum.2024-1115
Open Access
Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study
Christopher J. Edwards, Gerhard Krönke, Jérôme Avouac, Zhanguo Li, Fabrizio Conti, Alejandro Balsa, Daojun Mo, Ewa Haladyj, Peter Fischer, Masaru Tanaka, Yasushi Takita, Kohei Hagimori and Tsutomu Takeuchi

The Journal of Rheumatology April 1 2025, 52 (4) 316-322; DOI: https://doi.org/10.3899/jrheum.2024-0906
Open Access
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies
Victoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, Marina Magrey, Helena Marzo-Ortega, Philip J. Mease, Jessica A. Walsh, Maxime Dougados, Christine de la Loge, Carmen Fleurinck, Ute Massow, Thomas Vaux, Vanessa Taieb and Atul Deodhar

The Journal of Rheumatology January 1 2025, 52 (1) 23-32; DOI: https://doi.org/10.3899/jrheum.2024-0223
Open Access
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
Gerd R. Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S. Camp and Alan Kivitz

The Journal of Rheumatology July 1 2024, 51 (7) 663-672; DOI: https://doi.org/10.3899/jrheum.2023-1062
Open Access
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araújo, Ann Leung and Désirée van der Heijde

The Journal of Rheumatology August 1 2023, 50 (8) 1020-1028; DOI: https://doi.org/10.3899/jrheum.221022
Open Access
Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) Versus ASDAS: A Post Hoc Analysis of a Randomized Controlled Trial
Emilce E. Schneeberger, Gustavo Citera, Dario Ponce de Leon, Annette E. Szumski, Kenneth Kwok, Mariel Cutri and Maxime Dougados

The Journal of Rheumatology October 1 2022, 49 (10) 1100-1108; DOI: https://doi.org/10.3899/jrheum.211075
Open Access
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials
Louis Bessette, Eduardo Mysler, Cassandra D. Kinch, Kenneth Kwok, Tatjana Lukic, Phu Vinh On and Ronald F. van Vollenhoven

The Journal of Rheumatology June 1 2022, 49 (6) 566-576; DOI: https://doi.org/10.3899/jrheum.210707
Open Access
WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee
Philip G. Conaghan, Robert H. Dworkin, Thomas J. Schnitzer, Francis Berenbaum, Andrew G. Bushmakin, Joseph C. Cappelleri, Lars Viktrup and Lucy Abraham

The Journal of Rheumatology June 1 2022, 49 (6) 615-621; DOI: https://doi.org/10.3899/jrheum.210543

Main menu

User menu

Search

CLINICAL TRIALS

Pages

Content

Resources

Subscribers

More